Aarti Drugs Q2 net profit rises 83% on wider margins
According to TradingView, Aarti Drugs' Q2 net profit rose 83.2% year on year to ₹82.9 crore, revenue grew 26.6% and EBITDA margin reached 16.4%.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Aarti Drugs Ltd reported its second-quarter figures on Tuesday, November 3, with net profit up 83.2% year on year to ₹82.9 crore from ₹45.3 crore a year earlier, according to TradingView. Revenue climbed 26.6% to ₹826.2 crore from ₹652.8 crore.
EBITDA increased 60.6% to ₹135.4 crore from ₹84.3 crore. The EBITDA margin widened to 16.4% from 12.9%, an improvement of 350 basis points.
On the BSE, the shares closed at ₹465.00, up ₹11.20, or 2.47%.
why it matters
Margins growing faster than sales point to better cost control, and results like these typically draw investor attention to the company's stock and to India's pharmaceutical sector more broadly.
market impact
Aarti Drugs shares: strong profit and margin gains support the stock price
- Aarti Drugs shares pressure up — stronger profit and margins raise investor interest in the stock
tags
instruments
sources
- Aarti Drugs Q2 Results: Net profit soars 83% on stronger margins, revenue growth — TradingView, 3 November 2026 at 14:02 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗